OpenNeedle Ask your own

Question explored with the scientific record

Conversation so far

  1. 1 which receptors are likely hit too hard by this combo of meds taken near bedtime: clonazapam .5mg, mirtazapine 30mg, gabapentin 600mg, olanzapine 7.5mg
  2. 2 what effect do they have on weight both with and without terzepatide 7.5mg

Answered on this page ↓

what effect do they have on weight both with and without terzepatide 7.5mg

Oct 12, 2026 · 7 sources used · OpenNeedle synthesis
The short version: olanzapine and mirtazapine cause substantial weight gain; gabapentin and clonazepam have smaller effects; tirzepatide 7.5 mg can largely override them, but the net depends on dose and duration.

The evidence is clear on the weight-gain drugs. A systematic review of 257 trials found that olanzapine adds about 2.4 kg and mirtazapine about 1.5 kg on average [4]. Gabapentin adds about 2.2 kg [4]. Clonazepam was not in that review, but benzodiazepines are not known for major weight effects. In a controlled trial of healthy men, olanzapine caused 2.6 kg of weight gain in just two weeks, driven by increased calorie intake [2]. Mirtazapine's weight gain is well-documented: in one panic-disorder trial, 50% of patients reported weight gain as an adverse event [3].

Tirzepatide at 7.5 mg is a different story. In the SURMOUNT-1 extension, the 5 mg dose produced about 12.3% weight loss at 176 weeks, and the 10 mg dose about 18.7% [7]. A network meta-analysis found tirzepatide produces about 16.8% weight loss on average [6]. The 7.5 mg dose sits between those, so you would expect substantial weight loss—likely in the 10-15% range.

The key question is whether tirzepatide can overcome the weight-gain drugs. The evidence suggests yes, but with caveats. In a 24-week trial of metformin for olanzapine-induced weight gain, the placebo group gained 6.3 kg while the metformin group gained 5.5 kg—a modest difference [1]. Tirzepatide is far more potent than metformin. But the weight-gain drugs work through histamine H1 blockade and increased appetite [2], while tirzepatide works through GLP-1 and GIP receptors to reduce appetite and increase energy expenditure [5]. They are opposing mechanisms, and tirzepatide is the stronger force.

DrugTypical weight effectEvidence source
Olanzapine 7.5 mg+2.4 kg average; +2.6 kg in 2 weeks[4], [2]
Mirtazapine 30 mg+1.5 kg average; 50% report weight gain[4], [3]
Gabapentin 600 mg+2.2 kg average[4]
Clonazepam 0.5 mgMinimal; not in major reviews[4]
Tirzepatide 7.5 mg-10 to -15% of body weight[7], [6]

The evidence does not include a study that tested this exact combination. No trial compared the four drugs with and without tirzepatide. The individual pharmacology is well-documented, but the interaction is inferred. One concern: tirzepatide causes gastrointestinal side effects—nausea, vomiting, diarrhea—in a substantial fraction of patients [7], and those could be worsened by the sedation and slowed gut motility from the other drugs.

My call: tirzepatide 7.5 mg will likely produce net weight loss even with the other drugs, but the magnitude depends on how well you tolerate the combination. Confidence: moderate—the individual drug effects are well-studied, but the specific four-drug-plus-tirzepatide combination has not been tested.

Keep digging

Sources used 7

  1. Metformin for Prevention of Weight Gain and Insulin Resistance with Olanzapine: A Double-Blind Placebo-Controlled Trial The Canadian Journal of Psychiatry (2006) Thin

    This study investigates the efficacy of metformin in preventing weight gain and metabolic dysfunction in patients with schizophrenia treated with olanzapine, finding no significant differences in weight gain between metformin and placebo groups despite some metabolic improvement…

    DOI: 10.1177/070674370605100310
  2. Increased Food Intake and Energy Expenditure Following Administration of Olanzapine to Healthy Men Obesity (2010) Thin

    Short-term olanzapine in healthy men increases food intake and resting energy expenditure, causing about 2.6 kg of weight gain over two weeks, driven by increased caloric intake rather than reduced activity or insulin resistance, with early metabolic changes including altered ad…

    DOI: 10.1038/oby.2010.6
  3. Mirtazapine versus fluoxetine in the treatment of panic disorder Brazilian Journal of Medical and Biological Research (2001) Thin

    This study compares the efficacy and side effects of mirtazapine and fluoxetine in treating panic disorder, finding that both medications significantly improved symptoms, with mirtazapine showing a favorable profile in patient global evaluations despite a higher incidence of wei…

    DOI: 10.1590/S0100-879X2001001000010
  4. Drugs Commonly Associated With Weight Change: A Systematic Review and Meta-analysis The Journal of Clinical Endocrinology & Metabolism (2015) Thin

    This umbrella systematic review and meta-analysis synthesizes weight-change effects across 54 drugs from 257 randomized trials (84,696 participants), identifying which drugs are associated with weight gain or loss and highlighting methodological limitations to guide clinical cho…

    DOI: 10.1210/jc.2014-3421
  5. Tirzepatide Synergizes with Leptin on Weight Loss and Restoring Metabolic Homeostasis in Diet-induced Obesity Model Thin

    The study shows that tirzepatide (a GLP-1R/GIPR dual agonist) synergizes with leptin to enhance weight loss and restore metabolic homeostasis in diet-induced obesity, via increased energy expenditure and sensitized hypothalamic leptin signaling, with supportive clinical data lin…

    DOI: 10.64898/2025.12.18.695152
  6. SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss: A Network Meta-Analysis of Clinical Trials Journal of the Endocrine Society (2025) Thin

    This network meta-analysis compares tirzepatide and retatrutide for weight loss across randomized trials, finding retatrutide yields greater weight loss but with more adverse events than tirzepatide and highlighting the need for direct head-to-head trials.

    DOI: 10.1210/jendso/bvaf149.169
  7. Tirzepatide: the most Effective Drug Therapy for Prevention of type 2 Diabetes Clinical Endocrinology and Metabolism (2025) narrative review Strong

    In an extension of the SURMOUNT-1 trial, tirzepatide reduced progression to type 2 diabetes by 93% versus placebo over 176 weeks in adults with obesity and prediabetes, and is reported as the most effective drug therapy for diabetes prevention.

    DOI: 10.31579/2834-8761/073

Your question next

What do you want to know?

No question is too uncomfortable for the evidence. Bring yours.

Ask your question →